Long-term safety of subcutaneous immunotherapy with TO-204 in Japanese patients with house dust mite-induced allergic rhinitis and allergic bronchial asthma: Multicenter, open label clinical trial

Long-term safety of subcutaneous immunotherapy with TO-204 in Japanese patients with house dust mite-induced allergic rhinitis and allergic bronchial asthma: Multicenter, open label clinical trial

Background: To evaluate the long-term safety of subcutaneous immunotherapy with TO-204, a standardized house dust mite (HDM) allergen extracts, we conducted a multicenter, open label clinical trial. Methods: Japanese patients aged 5–65 years were eligible for the study, if they had HDM-induced aller...

Full description

Bibliographic Details
Main Authors: Takao Fujisawa, Terufumi Shimoda, Keisuke Masuyama, Kimihiro Okubo, Kohei Honda, Mitsuhiro Okano, Toshio Katsunuma, Atsuo Urisu, Yasuto Kondo, Hiroshi Odajima, Kazuyuki Kurihara, Makoto Nagata, Masami Taniguchi, Shoichiro Taniuchi, Satoru Doi, Tomoshige Matsumoto, Shoji Hashimoto, Akihiko Tanaka, Kensuke Natsui, Nahoko Abe, Hideki Ozaki
Format: Article
Language:English
Published: Elsevier 2018-07-01
Series:Allergology International
Online Access:http://www.sciencedirect.com/science/article/pii/S132389301730165X

Internet

http://www.sciencedirect.com/science/article/pii/S132389301730165X

Similar Items